Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ONCY Oncolytics Biotech	$1.00 -0.7%	$0.95	$0.33 ▼ $1.53	$100.86M	1.09	978,259 shs	226,309 shs
SKYE Skye Bioscience	$3.55 +1.3%	$3.63	$1.14 ▼ $7.47	$109.86M	2.21	664,267 shs	258,741 shs
SPRO Spero Therapeutics	$1.86 +1.4%	$2.53	$0.51 ▼ $3.22	$104.40M	1.39	1.91 million shs	406,142 shs
TENX Tenax Therapeutics	$5.97 -0.2%	$5.93	$3.25 ▼ $7.89	$27.24M	1.46	28,783 shs	8,885 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ONCY Oncolytics Biotech	+1.20%	-0.98%	-16.53%	+151.31%	+6.34%
SKYE Skye Bioscience	+5.11%	+11.46%	-6.17%	+68.67%	-33.46%
SPRO Spero Therapeutics	-0.54%	-5.18%	-21.12%	+162.18%	+46.40%
TENX Tenax Therapeutics	-0.66%	+1.18%	+0.84%	-3.63%	+44.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Earnings & Valuation
ONCY Oncolytics Biotech	1.7368 of 5 stars	3.4	3.0	0.0	2.0	0.0
SKYE Skye Bioscience	1.7584 of 5 stars	3.6	2.0	0.0	2.5	0.0
SPRO Spero Therapeutics	3.7799 of 5 stars	3.3	3.0	4.7	1.8	0.6
TENX Tenax Therapeutics	1.6899 of 5 stars	3.6	1.0	0.0	1.9	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ONCY Oncolytics Biotech	2.80	Moderate Buy	$5.00	398.50% Upside
SKYE Skye Bioscience	3.14	Buy	$15.50	337.24% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	169.54% Upside
TENX Tenax Therapeutics	3.25	Buy	$17.00	184.76% Upside

Current Analyst Ratings Breakdown

Latest TENX, SKYE, SPRO, and ONCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
8/14/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
8/13/2025	ONCY Oncolytics Biotech	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.04 per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$1.41 per share	N/A
SPRO Spero Therapeutics	$47.98M	2.18	N/A	N/A	$0.58 per share	3.20
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$22.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ONCY Oncolytics Biotech	-$23.14M	-$0.27	N/A	N/A	N/A	N/A	-438.11%	-143.90%	N/A
SKYE Skye Bioscience	-$26.57M	-$1.06	N/A	N/A	N/A	N/A	-76.03%	-69.20%	N/A
SPRO Spero Therapeutics	-$68.57M	-$0.98	N/A	N/A	N/A	-110.35%	-120.27%	-55.61%	N/A
TENX Tenax Therapeutics	-$17.60M	-$0.92	N/A	N/A	N/A	N/A	-31.34%	-30.39%	N/A

Latest TENX, SKYE, SPRO, and ONCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TENX Tenax Therapeutics	-$0.50	-$0.27	+$0.23	-$0.27	N/A	N/A
8/12/2025	Q2 2025	SPRO Spero Therapeutics	-$0.38	-$0.03	+$0.35	-$0.03	$11.00 million	$14.19 million
8/8/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.11	-$0.05	+$0.06	-$0.05	N/A	N/A
8/7/2025	Q2 2025	SKYE Skye Bioscience	-$0.34	-$0.44	-$0.10	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ONCY Oncolytics Biotech	N/A	2.88	2.88
SKYE Skye Bioscience	N/A	6.09	6.09
SPRO Spero Therapeutics	N/A	3.97	3.97
TENX Tenax Therapeutics	N/A	41.89	41.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ONCY Oncolytics Biotech	6.82%
SKYE Skye Bioscience	21.09%
SPRO Spero Therapeutics	25.60%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
ONCY Oncolytics Biotech	0.10%
SKYE Skye Bioscience	4.50%
SPRO Spero Therapeutics	5.50%
TENX Tenax Therapeutics	3.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ONCY Oncolytics Biotech	30	100.36 million	100.26 million	Not Optionable
SKYE Skye Bioscience	11	30.99 million	29.59 million	Optionable
SPRO Spero Therapeutics	150	56.28 million	53.18 million	Optionable
TENX Tenax Therapeutics	9	4.56 million	4.42 million	Not Optionable

TENX, SKYE, SPRO, and ONCY Headlines

Recent News About These Companies

Leerink Partnrs Has Negative Forecast for TENX Q3 Earnings

August 19 at 2:16 AM | americanbankingnews.com

William Blair Brokers Decrease Earnings Estimates for TENX

August 19 at 2:16 AM | americanbankingnews.com

Q3 EPS Estimate for Tenax Therapeutics Reduced by Analyst

August 18 at 2:43 AM | americanbankingnews.com

Equities Analysts Set Expectations for TENX FY2028 Earnings

August 17, 2025 | americanbankingnews.com

Tenax Posts Wider Loss in Fiscal Q2

August 14, 2025 | aol.comA

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

August 14, 2025 | msn.com

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

TENX Tenax Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Tenax Therapeutics Inc.

May 9, 2025 | barrons.com

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

April 16, 2025 | seekingalpha.com

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

April 16, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics (TENX) Gets a Buy from William Blair

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics: Q4 Earnings Snapshot

March 25, 2025 | timesunion.comT

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

Tenax Therapeutics Inc TENX

March 14, 2025 | morningstar.comM

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

March 6, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TENX, SKYE, SPRO, and ONCY Company Descriptions

Oncolytics Biotech NASDAQ:ONCY

$1.01 +0.01 (+0.50%)

As of 04:00 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Skye Bioscience NASDAQ:SKYE

$3.55 +0.05 (+1.54%)

As of 04:00 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Spero Therapeutics NASDAQ:SPRO

$1.86 +0.03 (+1.37%)

As of 04:00 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Tenax Therapeutics NASDAQ:TENX

$5.97 -0.01 (-0.17%)

Closing price 03:55 PM Eastern

Extended Trading

$6.02 +0.04 (+0.75%)

As of 04:01 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time